50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
NASDAQ:CRIS

Curis - CRIS News Today

$0.75
+0.05 (+7.17%)
(As of 09/28/2022 05:07 PM ET)
Add
Compare
Today's Range
$0.68
$0.76
50-Day Range
$0.70
$1.30
52-Week Range
$0.68
$8.20
Volume
890,104 shs
Average Volume
2.84 million shs
Market Capitalization
$68.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67
Get Curis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.



CRIS Media Mentions By Week

CRIS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRIS
News Sentiment

0.57

0.72

Average
Medical
News Sentiment

CRIS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRIS Articles
This Week

12

3

CRIS Articles
Average Week

SourceHeadline
markets.businessinsider.com logoWhy Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket - Markets Insider
markets.businessinsider.com - September 26 at 11:26 AM
MarketBeat logoCuris, Inc. Forecasted to Earn FY2022 Earnings of ($0.69) Per Share (NASDAQ:CRIS)
americanbankingnews.com - September 23 at 7:56 AM
MarketBeat logoCuris' (CRIS) Overweight Rating Reaffirmed at Cantor Fitzgerald
americanbankingnews.com - September 23 at 6:28 AM
benzinga.com logoKuCoin Announces Partnership with Legend Trading, A Leading Fiat-to-Crypto Payment Gateway - Benzinga
benzinga.com - September 22 at 10:18 AM
finance.yahoo.com logoCuris Announces Date for the 2nd Annual VISTA Symposium - Yahoo Finance
finance.yahoo.com - September 19 at 10:34 PM
reuters.com logoCRIS.A - Curis, Inc. | Stock Price & Latest News | Reuters
reuters.com - September 18 at 10:38 AM
nasdaq.com logoCuris To Present At H.C. Wainwright Global Investment Conference; Webcast At 4:00 PM ET - Nasdaq
nasdaq.com - September 14 at 7:16 PM
benzinga.com logoCuris (CRIS) – Curis to Present at Upcoming Healthcare Conferences in September - Benzinga
benzinga.com - September 7 at 9:20 AM
markets.businessinsider.com logoCuris Says FDS Allows Additional Patient Enrollment For TakeAim Leukemia Study
markets.businessinsider.com - August 31 at 5:35 PM
seekingalpha.com logoCuris leukemia study's monotherapy part gets FDA nod to resume enrollment, others still under partial hold
seekingalpha.com - August 31 at 5:35 PM
benzinga.com logoCuris Announces FDA Has Notified Co. It May Resume Enrollment Of Additional Patients In Monotherapy Dose - Benzinga
benzinga.com - August 30 at 6:27 PM
finance.yahoo.com logoFDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
finance.yahoo.com - August 30 at 12:51 PM
finance.yahoo.com logoCuris Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold
finance.yahoo.com - August 30 at 12:51 PM
benzinga.com logoCuris's Return On Capital Employed Insights - Benzinga
benzinga.com - August 24 at 3:40 PM
finance.yahoo.com logoCuris (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
finance.yahoo.com - August 19 at 6:20 PM
nasdaq.com logoRecent uptick might appease Curis, Inc. (NASDAQ:CRIS) institutional owners after losing 82% over the past year - Nasdaq
nasdaq.com - August 19 at 1:20 PM
uk.investing.com logoAnalyzing Curis Short Interest By Benzinga - Investing.com UK
uk.investing.com - August 19 at 2:07 AM
benzinga.com logoAnalyzing Curis Short Interest - Benzinga
benzinga.com - August 18 at 9:06 PM
benzinga.com logoCuris Announces FDA Lifts Partial Clinical Hold On The TakeAim Lymphoma Study Of Emavusertib - Benzinga
benzinga.com - August 18 at 4:05 PM
benzinga.com logoThinking about buying stock in Curis, bluebird bio, Nerdy, Sientra, or Aquestive Therapeutics? - Benzinga
benzinga.com - August 18 at 4:05 PM
investorplace.com logoWhy Is Curis (CRIS) Stock Up 20% Today? - InvestorPlace
investorplace.com - August 18 at 4:05 PM
seekingalpha.com logoCuris, Allarity top healthcare gainers; Blue Water, Accelerate lead losers' pack - Seeking Alpha
seekingalpha.com - August 18 at 11:05 AM
finance.yahoo.com logoFDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
finance.yahoo.com - August 18 at 11:05 AM
benzinga.com logoFDA Clears Curis' Lymphoma Study, Keeping Leukemia Trial Still Stalled
benzinga.com - August 18 at 9:55 AM
finance.yahoo.com logoInvestors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this past week
finance.yahoo.com - August 13 at 11:18 AM
streetinsider.com logoForm 3 CURIS INC For: Aug 05 Filed by: Duvall Diantha - StreetInsider.com
streetinsider.com - August 10 at 8:07 PM
benzinga.com logoGlobal TIM3 Inhibitors Drug Clinical Trials & Market Opportunities Report 2022: Market to Surpass $1 Bill - Benzinga
benzinga.com - August 8 at 10:24 PM
fool.com logoCuris (CRIS) Q2 2022 Earnings Call Transcript - The Motley Fool
fool.com - August 5 at 1:12 PM
finance.yahoo.com logoCuris (CRIS) Q2 2022 Earnings Call Transcript
finance.yahoo.com - August 5 at 8:12 AM
finance.yahoo.com logoCuris (CRIS) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 4 at 9:18 PM
finance.yahoo.com logoCuris Reports Second Quarter 2022 Financial Results and Business Update
finance.yahoo.com - August 4 at 4:18 PM
seekingalpha.com logoCuris Q2 2022 Earnings Preview (NASDAQ:CRIS) - Seeking Alpha
seekingalpha.com - August 4 at 11:17 AM
nytimes.com logoCovid. A Coma. A Stroke. José Parlá Returns From the Edge. - The New York Times
nytimes.com - July 31 at 3:56 PM
finance.yahoo.com logoCuris Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - July 29 at 6:04 PM
finance.yahoo.com logoCuris to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022 - Yahoo Finance
finance.yahoo.com - July 28 at 9:35 PM
finance.yahoo.com logoCuris to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022
finance.yahoo.com - July 28 at 4:35 PM
nasdaq.com logo6 Penny Stocks With 1,000% Upside Potential - Nasdaq
nasdaq.com - July 25 at 11:38 PM
mmajunkie.usatoday.com logoCoach Eric Nicksick thinks new gym leader Chris Curtis 'playing with house money' at UFC Fight Night 208 - MMA Junkie
mmajunkie.usatoday.com - July 22 at 6:05 PM
seekingalpha.com logoCuris: Asymmetric Risk And Reward (NASDAQ:CRIS) - Seeking Alpha
seekingalpha.com - July 17 at 5:16 AM
finance.yahoo.com logoWhat Kind Of Shareholders Hold The Majority In Curis, Inc.'s (NASDAQ:CRIS) Shares?
finance.yahoo.com - July 8 at 8:34 AM
finance.yahoo.com logoThe global bio decontamination market is projected to reach USD 227 million by 2027 from USD 159 million in 2022, at a CAGR of 7.3% from 2022 to 2027 - Yahoo Finance
finance.yahoo.com - June 29 at 5:17 AM
streetinsider.com logoAtreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer - StreetInsider.com
streetinsider.com - June 16 at 4:44 PM
finance.yahoo.com logoCuris Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress - Yahoo Finance
finance.yahoo.com - June 11 at 3:11 AM
finance.yahoo.com logoCuris Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress
finance.yahoo.com - June 10 at 8:36 AM
nasdaq.com logoCuris To Present At 2022 Jefferies Global Healthcare Conference; Webcast At 11:00 AM ET - Nasdaq
nasdaq.com - June 9 at 4:17 PM
finance.yahoo.com logoCelldex to Present at the 2022 Jefferies Global Healthcare Conference - Yahoo Finance
finance.yahoo.com - June 8 at 6:59 PM
finance.yahoo.com logoSensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation - Yahoo Finance
finance.yahoo.com - June 7 at 5:23 PM
finance.yahoo.com logoAerin Medical’s RhinAer® Demonstrates Long-term Safety and Efficacy for Treatment of Chronic Rhinitis in Newly Published Two-year Study - Yahoo Finance
finance.yahoo.com - June 7 at 12:22 PM
finance.yahoo.com logoMicrobion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane - Yahoo Finance
finance.yahoo.com - June 7 at 12:22 PM
finance.yahoo.com logoASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies - Yahoo Finance
finance.yahoo.com - June 7 at 6:44 AM
Get Curis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:CRIS) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.